Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group

The management of patients with glioma usually requires multimodality treatment including surgery, radiotherapy, and systemic therapy. Accurate neuroimaging plays a central role for radiotherapy planning and follow-up after radiotherapy completion. In order to maximize the radiation dose to the tumor and to minimize toxic effects on the surrounding brain parenchyma, reliable identification of tumor extent and target volume delineation is crucial. The use of positron emission tomography (PET) for radiotherapy planning and monitoring in gliomas has gained considerable interest over the last several years, but Class I data are not yet available. Furthermore, PET has been used after radiotherapy for response assessment and to distinguish tumor progression from pseudoprogression or radiation necrosis. Here, the Response Assessment in Neuro-Oncology (RANO) working group provides a summary of the literature and recommendations for the use of PET imaging for radiotherapy of patients with glioma based on published studies, constituting levels 1-3 evidence according to the Oxford Centre for Evidence-based Medicine.

Automated summary

Management of patients with glioma usually involves multimodality treatment, with accurate neuroimaging playing a central role in radiotherapy planning and follow-up. The use of PET imaging for radiotherapy planning and monitoring in gliomas has gained interest, but Class I data is currently lacking. PET has potential for response assessment and distinguishing tumor progression from pseudoprogression or radiation necrosis in glioma patients.